07:19 AM EDT, 03/13/2026 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) overnight Thursday reported a wider fourth-quarter net loss.

The company incurred a net loss of US$16.7 million, compared with a net loss of US$7.5 million for the prior year period. The company did not provide per share amounts. The wider net loss was due to higher research and development costs associated with the EP-104GI program and general and administrative costs.

Eupraxia had cash of US$80.5 million as of Dec. 31, 2025, up from US$33.1 million at the end of the fourth quarter of 2024. It says current cash reserves, proceeds from the US$62.3 million offering which closed in February, and future exercise of in-the-money warrants, will be sufficient to fund operations into the second half of 2028.

"2025 was a pivotal year for Eupraxia. We achieved significant clinical milestones in the development of our lead program, EP-104GI, and strengthened our balance sheet with two recent financings, positioning us well for our next phase of growth" said chief executive James Helliwell. "As we look ahead to an exciting year, we anticipate multiple clinical readouts from the ongoing RESOLVE trial and the initiation of additional clinical programs in new indications to further expand and strengthen our pipeline"